MX2021015756A - Polymorphs of a macrocyclic kinase inhibitor. - Google Patents

Polymorphs of a macrocyclic kinase inhibitor.

Info

Publication number
MX2021015756A
MX2021015756A MX2021015756A MX2021015756A MX2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A
Authority
MX
Mexico
Prior art keywords
polymorphs
kinase inhibitor
macrocyclic kinase
mammals
cancer
Prior art date
Application number
MX2021015756A
Other languages
Spanish (es)
Inventor
Han Zhang
Jing Liu
Wei Deng
Evan W Rogers
Yuelie Lu
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MX2021015756A publication Critical patent/MX2021015756A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This disclosure relates to polymorphs of (3<i>aR</i>,11<i>S</i>,20a<i>S</i>)-7-fluoro-11-methyl-2,3,3<i> a</i>,12,13,20a-hexahydro-1<i>H</i>,5<i>H</i>-17,19-(metheno)cyc lopenta[5,6][1,4]oxazino[3,4-<i>i</i>]pyrazolo[4,3-f]pyrido[3,2- <i>l</i>][1,4,8,10]oxatriazacyclotridecin-14(11<i>H</i>)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans.
MX2021015756A 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor. MX2021015756A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US202063036102P 2020-06-08 2020-06-08
PCT/US2020/037892 WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2021015756A true MX2021015756A (en) 2022-01-27

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015756A MX2021015756A (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor.

Country Status (14)

Country Link
US (1) US20220411439A1 (en)
EP (1) EP3986413A4 (en)
JP (1) JP2022537385A (en)
KR (1) KR20220046549A (en)
CN (1) CN114025765A (en)
AU (1) AU2020294627A1 (en)
BR (1) BR112021025786A2 (en)
CA (1) CA3143043A1 (en)
CO (1) CO2022000405A2 (en)
IL (1) IL288982A (en)
MX (1) MX2021015756A (en)
PE (1) PE20220135A1 (en)
TW (1) TW202115090A (en)
WO (1) WO2020257169A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (en) * 2021-06-25 2023-05-23 江南大学 Substituted chiral diaryl macrocyclic compounds as TRK inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3572416B1 (en) * 2014-01-24 2022-09-21 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (en) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Chiral diaryl macrocycles as modulators of protein kinases
LT3319969T (en) * 2015-07-06 2024-06-10 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
AU2016296878B2 (en) * 2015-07-21 2020-12-17 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
BR112020000772A2 (en) * 2017-07-14 2020-07-21 Glaxosmithkline Intellectual Property Development Limited leucine-rich repeat kinase 2 inhibitors
EP3728271B1 (en) * 2017-12-19 2022-09-28 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating diseases

Also Published As

Publication number Publication date
US20220411439A1 (en) 2022-12-29
AU2020294627A1 (en) 2022-02-17
BR112021025786A2 (en) 2022-02-01
PE20220135A1 (en) 2022-01-27
KR20220046549A (en) 2022-04-14
IL288982A (en) 2022-02-01
EP3986413A1 (en) 2022-04-27
CA3143043A1 (en) 2020-12-24
CO2022000405A2 (en) 2022-04-29
WO2020257169A1 (en) 2020-12-24
EP3986413A4 (en) 2023-06-14
JP2022537385A (en) 2022-08-25
TW202115090A (en) 2021-04-16
CN114025765A (en) 2022-02-08

Similar Documents

Publication Publication Date Title
MX2021008145A (en) Diaryl macrocycle polymorph.
MX2018000718A (en) Chiral diaryl macrocycles and uses thereof.
MX2021011438A (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases.
PH12016502115A1 (en) 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
WO2018141002A3 (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
EP3489238B8 (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
WO2006107771A3 (en) PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2023000782A (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy.
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
NZ751509A (en) Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
EA201290878A1 (en) IMIDAZO [1,2-a] DERIVATIVES AND THEIR APPLICATION FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS
NZ629230A (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
EA201892518A1 (en) SUBSTITUTED 5,6,7,8-TETRAHYDRO [1,2,4] TRIAZOLO [4,3-a] Pyridine-3 (2H) -OH and 2,5,6,7-TETRAHYDRO-3H-PIRROLO [2, 1-c] [1,2,4] TRIAZOL-3-HE AND THEIR APPLICATION
TW200745102A (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
MX2023007162A (en) Macrocycles and their use.
MX2023000503A (en) Macrocycles and their use.
MX2015000336A (en) Inhibitors of phosphodiesterase 10 enzyme.
WO2009111354A3 (en) Tyrosine kinase inhibitors
MX2018004517A (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicoti nonitrile derivatives and their use as irak inhibitors.
MX2021015756A (en) Polymorphs of a macrocyclic kinase inhibitor.
MX2022010945A (en) Therapeutic uses of macrocyclic compounds.
IL308997A (en) Pyrazolo[1,5-a]pyrimidine compound for the treatment of dermal disorders